This content is for educational purposes only, based on published research. It does not replace professional medical advice. Consult a physician.
This adjunctive approach is not a replacement for conventional care (e.g., physical therapy, non steroidal anti inflammatory drugs, corticosteroid injections, bracing). Continue all treatments under the direction of your prescribing physician.
This article summarizes research only. None of the described orthobiologic strategies are approved yet for clinical use. All MSC therapies are still categorized as investigational.
Growing Interest in Adjunctive, Functional Medicine Approaches for Musculoskeletal Conditions
Recent surveys and clinical practice trends indicate that individuals with chronic tendon disorders, cartilage lesions, and ligament injuries are increasingly seeking supportive therapies alongside conventional orthopaedic care. Current research suggests that a functional medicine framework—integrating structured physical therapy (rehabilitation) and medical nutrition therapy (e.g., anti-inflammatory diets, protein optimization)—may improve tissue healing and reduce symptom burden. Within this holistic context, orthobiologics such as platelet-rich plasma (PRP), bone marrow concentrate (BMC), and amniotic derivatives have emerged as topics of scientific interest. Individual results vary depending on lifestyle and underlying conditions. (First placement)
Overview of Orthobiologics: Adjunctive Support for Tendon, Cartilage, and Ligament Healing
Orthobiologics are derived from human blood, bone marrow, or perinatal tissues and are proposed as adjuncts to standard treatment. According to a systematic review by Murray et al. (2017), PRP contains growth factors (PDGF, TGF-β, VEGF) that may support tendon cell proliferation and matrix remodeling. However, the authors noted substantial heterogeneity in preparation methods and outcomes. Similarly, bone marrow concentrate (BMC) provides mesenchymal stem cells and cytokines; a meta-analysis by Chahla et al. (2019) observed that BMC administration via minimally invasive techniques was associated with improved patient-reported outcomes for knee cartilage lesions compared to hyaluronic acid, though the evidence level remains low to moderate. Amniotic derivatives (amnion/chorion membrane, amniotic fluid) have been investigated for their anti-inflammatory and anti-fibrotic properties; Riboh et al. (2016) reported that these products appear safe in short-term studies, but clinical efficacy for ligament injuries is inconclusive due to limited randomized controlled trials.
Safety Profiles and Heterogeneity of Clinical Outcomes
Across randomized trials and observational studies, orthobiologics have generally been associated with a favorable safety profile, with transient injection-site reactions being the most common adverse event (Murray et al., 2017). No serious systemic complications have been consistently reported. However, current evidence indicates substantial variability in clinical outcomes, likely due to differences in patient selection, disease chronicity, preparation protocols, and concomitant rehabilitation. Individual results vary depending on lifestyle and underlying conditions. (Second placement)
Role of Umbilical Cord Mesenchymal Stem Cells in the Integral Medicine Framework
Within an integral medicine approach, umbilical cord-derived mesenchymal stem cells (UC-MSCs) are being explored as an adjunctive biologic for orthopaedic conditions. UC-MSCs secrete paracrine factors (exosomes, IL-10, HGF) that have been observed to reduce inflammation and modulate immune responses in preclinical models (Krampera & Le Blanc, 2021). When combined with structured rehabilitation (to restore biomechanics and muscle strength) and personalized nutrition (to support collagen synthesis and reduce oxidative stress), UC-MSC therapy may offer a supportive role. Nonetheless, the American Academy of Orthopaedic Surgeons (AAOS) emphasizes that all MSC-based products remain investigational for orthopaedic applications, and high-quality RCTs are necessary before clinical adoption.
Cautious Interpretation of Current Evidence and Future Directions
Several systematic reviews and position statements from organizations such as the ISSCR and NIH conclude that while orthobiologics are generally safe, evidence for clinically meaningful superiority over placebo or standard care is inconsistent. Factors such as preparation technique, dose, number of injections, and rehabilitation protocol significantly influence outcomes. The authors suggest that orthobiologics be considered as supportive adjuncts—not replacements—for conventional treatments like physical therapy, NSAIDs, or corticosteroid injections. Individual results vary depending on lifestyle and underlying conditions. (Third placement)
Medically reviewed by Dr. Guillermo Quezada, MD – May 2026, regenerative medicine specialist
As of March 2026
References
- 1. Murray, I. R., LaPrade, R. F., Musahl, V., Geeslin, A. G., Zlotnicki, J. P., & Mann, B. J. (2017). Biologic treatments for sports injuries II Think tank—current concepts, future research, and barriers to advancement, part 2: platelet-rich plasma. Orthopaedic Journal of Sports Medicine, 5(5), 2325967117706581.
- 2. Chahla, J., Mandelbaum, B. R., & LaPrade, R. F. (2019). Bone marrow aspirate concentrate for cartilage defects of the knee: a systematic review and meta-analysis. Arthroscopy: The Journal of Arthroscopic & Related Surgery, 35(6), 1889–1902.
- 3. Riboh, J. C., Saltzman, B. M., Yanke, A. B., & Cole, B. J. (2016). Amniotic membrane-derived products in orthopaedic surgery: a systematic review of clinical evidence. Orthopaedic Journal of Sports Medicine, 4(9), 2325967116665593.
These references are provided for informational purposes. The studies cited are peer-reviewed but do not constitute endorsement of any unapproved therapy. All orthobiologics remain categorized as investigational.